Get the Stockscreener App
1.52
9.24%
0.12
Neumora Therapeutics Inc stock is traded at $1.52, with a volume of 1.01M.
It is up +9.24% in the last 24 hours and up +92.86% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
1.01M
Relative Volume:
0.84
Market Cap:
$245.86M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.5997
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+44.28%
1M Performance:
+92.86%
6M Performance:
-25.40%
1Y Performance:
-87.15%
1-Day Range:
$1.40
$1.6199
1-Week Range:
$1.013
$1.6199
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.52 | 164.98M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.72 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.49 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.67 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.97 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.72 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at Mizuho - MarketBeat
Mizuho raises Neumora Therapeutics stock price target on new drug candidate - Investing.com Canada
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
How Neumora Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
What makes Neumora Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Neumora Therapeutics (NMRA) Soars 33.02% on Drug Trial Advancement - AInvest
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 By Investing.com - Investing.com South Africa
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target - TipRanks
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 - The Manila Times
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 - Investing.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus Target Price from Analysts - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by California State Teachers Retirement System - Defense World
72,622 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Shareholders Filed a Lawsuit Against Neumora Therapeutics for Misleading Drug Trial Claims - TradingView
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts - Defense World
Ameriprise Financial Inc. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks
BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.
26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World
Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q1 2025: Unraveling Contradictions in KOASTAL Trials and Patient Selection Strategies - AInvest
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World
Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia
The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India
Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com
What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World
William Blair Analysts Increase Earnings Estimates for NMRA - Defense World
Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
3.69%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):